Mechanisms linking the metabolic syndrome and cardiovascular disease: Role of hepatic insulin resistance

Journal of Tehran University Heart Center

Volumn 4, Issue 2, 2009, Pages 77-84

  Meshkani, Reza ^a   Adeli, Khosrow ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cardiovascular diseases; Insulin resistance; Metabolic syndrome X

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE 1B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY ACID METABOLISM; GENETIC ASSOCIATION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HORMONE ACTION; HUMAN; HYPERCOAGULABILITY; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; LIVER FUNCTION; METABOLIC SYNDROME X; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 77953438293     PISSN: 17358620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepat 2007;47:142-156.
2. Muniyappa R, Montagnani M, Kon Koh K, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007;28:463-491.
3. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006;119:S10-16.
4. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Ann Rev Nut 2005;25:391-406.
5. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 2007;44:232-263.
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen N, Kumpulalo J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
7. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-483.
8. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
9. Meshkani R, Taghikhani M, Larijani B, Khatami E, Khoshbin E. Adeli K. The relationship between homeostasis model assessment and cardiovascular disease risk factors in Iranian subjects with normal fasting glucose and normal glucose tolerance. Clin Chem Acta 2006;371:169-175.
10. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997;46:524-527.
11. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-176.
12. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182-186.
13. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002;27:235-241.
14. Kaszubska W, Falls HD, Schaefer VG, Haasch D, Frost L, Hessler P, Kroeger PE, White DW, Jirousek MR, Trevillyan JM. Protein tyrosine phosphatase 1B negatively regulates leptin signalling in a hypothalamic cell line. Mol Cell Endocrinol 2002;195:109-118.
15. Ahmad F, Azevedo Jl, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscle Protein-Tyrosine Phosphatase activity and expression in ensulin-resistant human obesity and diabetes. J Clin Invest 1997;100:449-458.
16. Meshkani R, Taghikhani M, Al-Kateb H, Larijani B, Khatami S, Sidiropoulos GK, Hegele RA, Adeli K. Polymorphisms within the protein tyrosine phosphatase IB (PTPN1) gene promoter: functional characterization and association with type 2 diabetes and related metabolic traits. Clin Chem 2007;53:1585-1592.
17. Meshkani R, Taghikhani M, Mosapour A, Larijani B, Khatami S, Khoshbin E, Ahmadvand D, Saeidi P, Maleki A, Yavari K, Nasoohi N, Adeli K. 1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population. Arch Med Res 2007;38:556-562.
18. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signalling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000;6:87-97.
19. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ, Kahn CR. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-569.
20. Adiels M, Olofsson S, Taskinen M, Boren J. Overproduction of very low density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-1236.
21. Reaven GM, Mondon CE. Effect of in vivo plasma insulin levels on the relationship between perfusate free fatty acid concentration and triglyceride secretion by perfused rat livers. Horm Metab Res 1984;16:230-232.
22. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976;12:563-571.
23. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev 2007;65:S39-46.
24. Lewis GF, Carpentier A, Adeli k, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229.
25. Au CS, Wagner A, Chong T, Qiu W, Sparks JD, Adeli K. Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1/PKBalpha. Metabolism 2004;53:228-235.
26. Taghibiglou C, Van-Inderstine S, Letien H, Fantus G, Lewis GF, Adeli K. Hepatic VLDL-apo B overproduction is associated with attenuated hepatic insulin signalling in a fructose-fed hamster model of insulin resistance: evidence for increased expression of PTP-1B and decreased abundance of ER-60 protease. J Biol Chem 2002;277:793-803.
27. Adeli K, Macri J, Mohammadi A, Kito M, Urade R, Cavallo D. Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells. J Biol Chem 1997;272:22489-22494.
28. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in non insulin-dependent diabetes mellitus. Atherosclerosis 1993;104:69-77.
29. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003;36:421-429.
30. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-48490.
31. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-339.
32. Voleti B, Agrawal A. Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kB on the proximal promoter. J Immunol 2005;175:3386-3390.
33. Alessi M, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200-2207.
34. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
35. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996;97:37-46.
36. Nagi DK, Tracy R, Pratley R. Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. Metabolism 1996;45:1243-1247.
37. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996;2:568-582.
38. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system, obes rev 2002;3:85-101.
39. Raynaud E, Perez-Martin A, Brun J, Aissa-Benhaddad A, Fedou C, Mercier J. Relationships between fibrinogen and insulin resistance. Atherosclerosis 2000;150:365-370.
40. Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97-105.
41. Popa C, Riel PLCM, Meer WM, Stalenhoef AFH. The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-762.
42. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995;136:2143-2149.
43. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008;14:222-231.
44. Arita, Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miygava J, Hotta K, shimomura I. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83
45. Anner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002;18:S5-9.
46. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-444.
47. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115-126.
48. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005;31:429-439.
49. Singh SK, Suresh MV, Voleti B, Agrawal A. The connection between C-reactive protein and atherosclerosis. Ann Med 2008;40:110-120.